{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:07:41Z","timestamp":1791328061001,"version":"4.3.1"},"reference-count":28,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1136\/jnnp-2016-313541","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T01:38:39Z","timestamp":1478137119000},"page":"119-125","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":81,"title":["Doxycycline in early CJD: a double-blinded randomised phase II and observational study"],"prefix":"10.1136","volume":"88","author":[{"given":"Daniela","family":"Varges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrike","family":"Manthey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Ponto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter J","family":"Schulz-Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Krasnianski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Breithaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Fincke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Friede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Zerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,11,2]]},"reference":[{"key":"key-10.1136\/jnnp-2016-313541-1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/archneur.63.4.497","article-title":"Emerging pharmacotherapies for Creutzfeld-Jakob disease","volume":"63","author":"Korth","year":"2006","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2016-313541-2","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1093\/brain\/awl150","article-title":"A systematic review of prion therapeutics in experimental models","volume":"129","author":"Trevitt","year":"2006","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2016-313541-3","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1212\/01.wnl.0000308955.25760.c2","article-title":"Systematic review of therapeutic interventions in human prion diseases","volume":"70","author":"Stewart","year":"2008","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313541-4","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/brain\/awt075","article-title":"Human prion diseases: progress in clinical trials","volume":"136","author":"Zerr","year":"2013","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2016-313541-5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14656566.2010.514903","article-title":"Rapidly progressive dementias and the treatment of human prion diseases","volume":"12","author":"Appleby","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"key-10.1136\/jnnp-2016-313541-6","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1006\/jmbi.2000.3840","article-title":"Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro","volume":"300","author":"Tagliavini","year":"2000","journal-title":"J Mol Biol"},{"key":"key-10.1136\/jnnp-2016-313541-7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1871526510909010023","article-title":"Tetracyclines and prion infectivity","volume":"9","author":"Forloni","year":"2009","journal-title":"Infect Disord Drug Targets"},{"key":"key-10.1136\/jnnp-2016-313541-8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","article-title":"Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"13","author":"Ha\u00efk","year":"2014","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2016-313541-9","first-page":"361","article-title":"Human transmissible spongiform encephalopathies","volume":"47","author":"WHO","year":"1998","journal-title":"Wkly Epidemiol Rec"},{"key":"key-10.1136\/jnnp-2016-313541-10","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1093\/brain\/awp191","article-title":"Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease","volume":"132","author":"Zerr","year":"2009","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2016-313541-11","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1212\/01.WNL.0000113764.35026.EF","article-title":"Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study","volume":"62","author":"Otto","year":"2004","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313541-12","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3233\/JAD-2010-101527","article-title":"Amyloid-b 1\u201342 levels are modified by apolipoprotein E e4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer's disease","volume":"23","author":"Varges","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"key-10.1136\/jnnp-2016-313541-13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1212\/WNL.55.6.811","article-title":"Analysis of EEG and CSF 14\u20133-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease","volume":"55","author":"Zerr","year":"2000","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313541-14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s004390051096","article-title":"Molecular genetics of human prion diseases in Germany","volume":"105","author":"Windl","year":"1999","journal-title":"Hum Genet"},{"key":"key-10.1136\/jnnp-2016-313541-15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in metaanalyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"key-10.1136\/jnnp-2016-313541-16","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1212\/01.WNL.0000160117.56690.B2","article-title":"Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada","volume":"64","author":"Ladogana","year":"2005","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313541-17","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1474-4422(09)70049-3","article-title":"Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial","volume":"8","author":"Collinge","year":"2009","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2016-313541-18","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1212\/WNL.0b013e3182a9f3b4","article-title":"Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease","volume":"81","author":"Geschwind","year":"2013","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313541-19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1001\/jamaneurol.2015.4885","article-title":"Clinical trial simulations based on genetic stratification and the natural history of a functional outcome measure in Creutzfeldt-Jakob disease","volume":"73","author":"Mead","year":"2016","journal-title":"JAMA Neurol"},{"key":"key-10.1136\/jnnp-2016-313541-20","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.clinph.2005.12.007","article-title":"EEG in Creutzfeldt-Jakob disease","volume":"117","author":"Wieser","year":"2006","journal-title":"Clin Neurophysiol"},{"key":"key-10.1136\/jnnp-2016-313541-21","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/jnnp-2014-309871","article-title":"A case of variably protease-sensitive prionopathy treated with doxycyclin","volume":"86","author":"Assar","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2016-313541-22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1136\/jnnp-2014-310127","article-title":"Rethinking of doxycycline therapy in Creutzfeldt-Jakob disease","volume":"86","author":"Pocchiari","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2016-313541-23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/1871526510909010092","article-title":"Therapeutic trails in human transmissible spongiform encephalopaths: recent advances and problems to address","volume":"1","author":"Zerr","year":"2009","journal-title":"Infect Disord Drug Targets"},{"key":"key-10.1136\/jnnp-2016-313541-24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/archneur.1983.04050080055010","article-title":"The effect of amantadine on arousal and EEG patterns in Creutzfeldt-Jakob disease","volume":"40","author":"Terzano","year":"1983","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2016-313541-25","first-page":"47","article-title":"[Amantadine in Creutzfeldt-Jakob disease. Review of the literature and case contribution]","volume":"30","author":"Neri","year":"1984","journal-title":"Riv Neurobiol"},{"key":"key-10.1136\/jnnp-2016-313541-26","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1468-1331.2008.02108.x","article-title":"Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK","volume":"15","author":"Bone","year":"2008","journal-title":"Eur J Neurol"},{"key":"key-10.1136\/jnnp-2016-313541-27","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1440-1789.2009.01058.x","article-title":"Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases","volume":"29","author":"Tsuboi","year":"2009","journal-title":"Neuropathology"},{"key":"key-10.1136\/jnnp-2016-313541-28","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1212\/01.WNL.0000148596.15681.4D","article-title":"Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects","volume":"63","author":"Ha\u00efk","year":"2004","journal-title":"Neurology"}],"container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2016-313541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T18:03:32Z","timestamp":1601057012000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2016-313541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,2]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,1,13]]},"published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1136\/jnnp-2016-313541"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2016-313541","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,2]]}}}